Literature DB >> 18286348

High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.

Jean-Marc Sabaté1, Pauline Jouët, Florence Harnois, Charlotte Mechler, Simon Msika, Maggy Grossin, Benoît Coffin.   

Abstract

BACKGROUND: With the increasing prevalence of obesity, non-alcoholic fatty liver disease (NAFLD) has become a major cause of liver diseases. Small intestinal bacterial overgrowth (SIBO) could be related to NAFLD. Our aim was to determine the prevalence of SIBO and its relationship with liver lesions in morbidly obese patients.
METHODS: A glucose hydrogen (H(2)) breath test (positive if fasting breath H(2) concentration > 20 ppm and/or an increase of > 10 ppm over baseline within the first 2 h) was performed in obese patients referred for bariatric surgery (body mass index [BMI] > 40 kg/m(2) or > 35 in association with comorbidities) and in healthy non-obese subjects. In obese patients, a surgical liver biopsy was performed.
RESULTS: One hundred and forty-six patients (129 women, age [mean+/-SE]: 40.7 +/- 11.4 years) were prospectively included in the study. The mean BMI was 46.1+/-6.4 kg/m(2). A liver biopsy was available in 137 patients and a breath test in 136. The frequency of positive breath tests was higher in obese patients (24/136, 17.1%) than in healthy subjects (1/40, 2.5%; P=0.031). In the univariate analysis, SIBO was not associated with clinical variables, but tended to be associated with more frequent severe hepatic steatosis (26.3 vs. 10.3%, P=0.127), whereas the frequency of sinusoidal or portal fibrosis, lobular necrosis and non-alcoholic steatohepatitis (NASH) were not different. In the multivariate analysis, SIBO (P=0.005) and the presence of a metabolic syndrome (P=0.006) were independent factors of severe hepatic steatosis.
CONCLUSION: In morbidly obese patients, bacterial overgrowth prevalence is higher than in healthy subjects and is associated with severe hepatic steatosis.

Entities:  

Mesh:

Year:  2008        PMID: 18286348     DOI: 10.1007/s11695-007-9398-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  47 in total

1.  Interdigestive gastroduodenal motility and cycling of putative regulatory hormones in severe obesity.

Authors:  O Pieramico; P Malfertheiner; D K Nelson; B Glasbrenner; H Ditschuneit
Journal:  Scand J Gastroenterol       Date:  1992-07       Impact factor: 2.423

2.  Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier?

Authors:  D A Elphick; T S Chew; S E Higham; N Bird; A Ahmad; D S Sanders
Journal:  Gerontology       Date:  2005 Nov-Dec       Impact factor: 5.140

3.  Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.

Authors:  A Attar; B Flourié; J C Rambaud; C Franchisseur; P Ruszniewski; Y Bouhnik
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

4.  Breath hydrogen in bacterial overgrowth.

Authors:  B Flourie; J Turk; M Lemann; C Florent; R Colimon; J C Rambaud
Journal:  Gastroenterology       Date:  1989-04       Impact factor: 22.682

5.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

6.  Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease.

Authors:  Raphael B Merriman; Linda D Ferrell; Marco G Patti; Shiobhan R Weston; Mark S Pabst; Bradley E Aouizerat; Nathan M Bass
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Non-alcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth.

Authors:  M Nazim; G Stamp; H J Hodgson
Journal:  Hepatogastroenterology       Date:  1989-10

9.  Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth.

Authors:  S N Lichtman; E E Okoruwa; J Keku; J H Schwab; R B Sartor
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

10.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

View more
  67 in total

1.  Small intestinal bacterial overgrowth in patients with morbid obesity.

Authors:  Pauline Jouet; Benoit Coffin; Jean-Marc Sabate
Journal:  Dig Dis Sci       Date:  2011-02       Impact factor: 3.199

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance.

Authors:  Amit H Sachdev; Mark Pimentel
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

4.  Obesity and the gut microbiome: Striving for causality.

Authors:  Isaac T W Harley; Christopher L Karp
Journal:  Mol Metab       Date:  2012-08-03       Impact factor: 7.422

5.  Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8.

Authors:  Ahmed Abu Shanab; Paul Scully; Orla Crosbie; Martin Buckley; Liam O'Mahony; Fergus Shanahan; Sanaa Gazareen; Eileen Murphy; Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2010-11-03       Impact factor: 3.199

Review 6.  Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.

Authors:  Irina A Kirpich; Luis S Marsano; Craig J McClain
Journal:  Clin Biochem       Date:  2015-07-04       Impact factor: 3.281

7.  The role of malabsorption in bariatric surgery.

Authors:  Vivek N Prachand; John C Alverdy
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

Review 8.  Role and effective therapeutic target of gut microbiota in NAFLD/NASH.

Authors:  Qun Liu; Shousheng Liu; Lizhen Chen; Zhenzhen Zhao; Shuixian Du; Quanjiang Dong; Yongning Xin; Shiying Xuan
Journal:  Exp Ther Med       Date:  2019-07-17       Impact factor: 2.447

9.  Consequences of Small Intestinal Bacterial Overgrowth in Obese Patients Before and After Bariatric Surgery.

Authors:  Jean-Marc Sabate; Muriel Coupaye; Séverine Ledoux; Benjamin Castel; Simon Msika; Benoit Coffin; Pauline Jouet
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

Review 10.  Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Authors:  Shahinul Alam; Golam Mustafa; Mahabubul Alam; Nooruddin Ahmad
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.